Pronunciation: (AL-oh-PURE-ee-nahl)
Class: Agent for gout, Antimetabolite
Trade Names:
Aloprim
- Powder for injection, lyophilized 500 mg
Trade Names:
Zyloprim
- Tablets 100 mg
- Tablets 300 mg
Apo-Allopurinol (Canada)
Pharmacology
Inhibits xanthine oxidase, the enzyme responsible for conversion of hypoxanthine to xanthine and then to uric acid.
Pharmacokinetics
Absorption
About 90% absorbed from GI tract. T max is 1.5 h (allopurinol) and 4.5 h (oxipurinol). C max is 3 mcg/mL (allopurinol 300 mg) and 6.5 mcg/mL (oxipurinol).
Metabolism
Rapidly oxidized to oxipurinol.
Elimination
About 20% is excreted in the feces. Allopurinol is essentially cleared by glomerular filtration, whereas oxipurinol is reabsorbed in the kidney tubules. T 1/2 , plasma is about 1 to 2 h (allopurinol) and about 15 h (oxipurinol).
Onset
Uric acid decreases in about 2 to 3 days.
Peak
May require a week or more of treatment.
Duration
Xanthine oxidase inhibition is maintained over 24 h; however, uric acid levels may not return to pretreatment levels until 7 to 10 days following cessation of therapy.
Indications and Usage
Tablets
Treatment of primary or secondary gout, hyperuricemia resulting from chemotherapy for malignancies, recurrent calcium oxalate renal calculi.
Tablets and injections
Management of patients with leukemia, lymphoma, and solid tumor malignancies when concurrently receiving cancer therapy that causes elevations of serum and urinary uric acid levels. Use injection in patients who cannot tolerate oral therapy.
Unlabeled Uses
Prevention of fluorouracil-induced stomatitis and fluorouracil-induced granulocyte suppression.
Contraindications
Standard considerations.
Dosage and Administration
Control of Gout/Hyperuricemia
Adults
PO 100 to 800 mg/day. For amounts over 300 mg, give divided doses.
Secondary Hyperuricemia Associated with Malignancies
Children 6 to 10 yr of age
PO 300 mg/day.
Children under 6 yr of age
PO 150 mg/day.
Prevention of Uric Acid Nephropathy in Vigorous Chemotherapy of Neoplastic Disease
Adults
PO 600 to 800 mg/day for 2 to 3 days.
Reduction of Risk of Acute Gouty Attacks
Adults (initial dose)
PO 100 mg/day, increased by 100 mg at weekly intervals until adequate response is achieved or max recommended dose (800 mg/day) is reached.
Leukemia, Lymphoma, Solid Tumor Malignancies
Adults
IV 200 to 400 mg/m 2 /day (max 600 mg/day).
Children
IV Starting dose 200 mg/m 2 /day.
Storage/Stability
Reconstituted solution
Store reconstituted solution at 20° to 25°C; do not refrigerate or dilute product.
Tablets
Store tablets in tightly closed container in cool location.
Unreconstituted solution
Store unreconstituted powder at room temperature.
Drug Interactions
Amoxicillin increased risk of rash when allopurinol given with amoxicillin
Ampicillin increased risk of rash when allopurinol given with ampicillin
Azathioprine allopurinol enhances effects and increases toxicity of azathioprine (reduce dose of azathioprine to one quarter of usual dose)
Capecitabine avoidance of allopurinol advised by manufacturer of capecitabine Capecitabine is a prodrug of fluorouracil
Captopril increased risk of toxicity when allopurinol given with captopril especially in renal impairment
Ciclosporin allopurinol possibly increases plasma concentration of ciclosporin (risk of nephrotoxicity)
Coumarins allopurinol possibly enhances anticoagulant effect of coumarins Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control
Didanosine allopurinol possibly increases plasma concentration of didanosine Antacids in tablet formulation may affect absorption of other drugs
Diuretics, Thiazide and related increased risk of hypersensitivity when allopurinol given with thiazides and related diuretics especially in renal impairment
Mercaptopurine allopurinol enhances effects and increases toxicity of mercaptopurine (reduce dose of mercaptopurine to one quarter of usual dose)
Theophylline allopurinol possibly increases plasma concentration of theophylline
Adverse Reactions
CNS
Drowsiness; generalized seizure (injectable); headache; neuritis; paresthesias; peripheral neuropathy.
Dermatologic
Allergic vasculitis; alopecia; ecchymosis; skin rash. Allergic reactions may be severe and sometimes fatal.
EENT
Epistaxis; myopathy; taste disturbance.
GI
Abdominal pain; diarrhea; dyspepsia; gastritis; granulomatous changes; nausea; vomiting.
Genitourinary
Renal failure; uremia.
Hematologic
Bone marrow depression; eosinophilia; leukocytosis; leukopenia; thrombocytopenia.
Hepatic
Cholestatic jaundice; elevated liver enzymes; hepatic necrosis; hepatitis; reversible hepatomegaly.
Other
Acute gouty attacks; arthralgia; fever; myopathy; necrotizing angiitis.
Precautions
Pregnancy
Category C .
Lactation
Excreted in breast milk.
Children
Allopurinol is rarely indicated for use in children, except for hyperuricemia resulting from malignancy or with certain rare inborn errors of purine metabolism.
Hypersensitivity
Discontinue drug at first appearance of skin rash or other signs of allergic reaction. Rash may be followed by more severe hypersensitivity reactions and, rarely, death.
Renal Function
Reduced dose is given in patients with this condition. Drug may exacerbate renal failure in certain patients.
Acute gouty attacks
May occur during initial stages of therapy.
Bone marrow depression
Reported in patients given allopurinol.
Patient Information
* Encourage patient to focus on weight loss or control.
* Tell patient to avoid purine-rich foods (eg, organ meats).
* Caution patient to avoid excessive intake of alcohol.
* Explain that gouty attacks may not end for 2 to 6 wk after beginning therapy.
* Instruct patient to stop taking medication and notify health care provider if rash or flu-like symptoms develop.
* Advise patient that drug may cause drowsiness, and to use caution while driving or performing other tasks requiring mental alertness.
Sunday, July 26, 2009
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment